Galectin Therapeutics (GALT) Long-Term Debt Issuances (2021)
Galectin Therapeutics' quarterly Long-Term Debt Issuances came in at $10.0 million in Q4 2021, little changed quarter-over-quarter from $10.0 million in Q3 2021.
Galectin Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $10.0 million in Q4 2021.
- For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2022 stood at $20.0 million (changed N/A YoY), and the FY2021 full-year result was $30.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2021 stood at $10.0 million, roughly flat from $10.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $10.0 million in Q3 2021, with the low at $10.0 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |